ClinicalTrials.gg
CompletedNCT04941651TOOLBARUpdated Sep 30, 2026

Efficacy of Telenutrition for the Treatment of Overweight Patients With Obesity and/or High Cardiometabolic Risk

An interventional study of OBE-COACH program and Connected devices in Overweight and Obesity, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.

Enrollment
9th of 38
346 · median 110
Started
2024
with 2 others
No phase
30 of 58
9 open now
Registered
42nd of 58
by date

Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2024, is one of 30 with no phase, and was the 42nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The OBE-COACH program is an automated online nutritional coaching service that was evaluated in its first version (MXS-CARE program) in a clinical trial coordinated by our team, in type 2 diabetic patients with abdominal obesity. Results have confirmed the efficiency of the program to improve lifestyle habits, including the 4-month diet, and to reduce weight and HbA1c levels.

Based on our experience and the scientific literature, the investigators assume that adherence to the program may diminish in the long term to the point of calling into question its efficiency. So IRIADE compagny developed an enhanced program called OBE-COACH. The OBE-COACH program has been specifically designed to facilitate long-term user adherence. The OBE-COACH program, integrates a bidirectional interactive link between the patient and an automated support system (IRIADE-MED system) associated with an inexpensive remote human support.

In the TOOLBAR study, the investigators will evaluate the efficiency of the OBE-COACH solution in a population of obese patients or overweight persons with at least one cardiometabolic risk factor.

A group of patients will have access to the OBE-COACH program. It will be compared to a control group which will receive an e-learning program with free access to advice sheets via the web, to a menu generator, videos and a catalog of physical activity, (resources made available by the web site www.mangerbouger.fr (public health France, ministry in charge of health) . Indeed, the investigators judged that the loss of patients during follow-up would be greater if e-learning was not offered in the control group.

Read the detailed description

The management of patients in the TOOLBAR study will be in accordance with French recommendations: a patient who is overweight should benefit from a dietary, physical activity, psychological assistance and medical monitoring advices which can be provided by a general practitioner. In the control group, subjects have access to an e-learning program, including free access via the web to a nutritional information portal and to automated tools providing information and advice for adopting a balanced, low-carb diet and to practice physical activity in line with the guidelines of the national health nutrition plan (PNNS). However, this group will not have access to the OBE-COACH program. The usual follow-up with the attending doctor will be continued.

Patients will be assessed at baseline, 6 months and 12 months. In an ancillary study they could be also assessed at 24 months.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

Keywords

  • Overweight patients
  • Obesity
  • Cardiometabolic risk
  • telenutrition
  • online nutritional coaching service
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's enrollment of 346 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women 18 to 75 years
  • Obesity defined by a > 30 kg / m2 or a BMI> 25 kg / m2 with the presence of at least one major cardiometabolic risk factors among the followings: dyslipidemia, hypertension, diabetes, prediabetes
  • Stable weight in the last six months (weight variation \< 4 kg peak-to-peak)
  • Access and current use of internet, possession of an email address and a smartphone.
  • Understanding and reading French
  • Patient not currently following a nutritional monitoring and not having planned to be engaged in a nutritional monitoring during the coming year

Exclusion criteria

Exclusion Criteria:

  • Excessive alcohol consumption > 30 g / day -Pregnant or breastfeeding woman
  • symptomatic cardiovascular disease : angina, lower extremity arterial occlusive disease, stroke or myocardial infarction dating of less than 6 months.
  • Uncontrolled psychiatric illness
  • Patients receiving or about to receive during the study period a systemic or local treatment susceptible to interfere with the evaluation of the primary criteria (, antipsychotics, tricyclic antidepressants) except if these treatments have been stable for at least 6 months without a plan to modify the dose during the 12 months of the study
  • Adhering to a prescribed diet for weight loss, in the past 3 months
  • Person with a severe eating disorder: bulimia, binge eating disorder according to criteria - Presence of celiac disease, Crohn's disease or other metabolic disorder or condition affecting nutritional needs such as allergies or food intolerances (except partial lactose intolerance)
  • Anticipated difficulties in following the patient
  • Lack of social coverage in France
  • Lack of written or electronic
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
346 participants (actual)

Study arms

  • Experimental
    OBE-COACH program

    The OBE-COACH experimental group: access to the complete OBE-COACH program

    Behavioral: OBE-COACH program · Device: Connected devices · Device: Connected Activity Tracer

  • Active comparator
    e-learning program

    The control group: access to an e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health) and provision of connected devices (auto-tensiometer and balance).

    Device: Connected devices · Device: Connected Activity Tracer · Behavioral: e-learning program

Interventions

  • BehavioralOBE-COACH program

    OBE-COACH works through private exchanges between the user and an automatic generator of recommendations, advice and messages of encouragement. Web focus groups are propoposed by specialist to respond to the questions of the participants and a tele-interview at 6 months with a dietetician to encourage and assist the patient to make the best use of the program. The program is divided into missions to perform. These missions are grouped into 10 families. The completion of each mission and the correct answers to the quiz offer points and bonuses. To promote better adherence to the program, missions are not repetitive. They are proposed to surprise the user and constantly renew his desire to connect to the program and achieve goals. The intensity level of the program is selected by the user at any time.

  • DeviceConnected devices

    Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program. The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate. The balance (Web coach premium, Terraillon) is a connected scale to collect body weight.

  • DeviceConnected Activity Tracer

    The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.

  • Behaviorale-learning program

    e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health)

07

What researchers measure

Primary outcomes

  1. Weight reduction of at least 5% between 0 and 12 months.

    Weight reduction of at least 5% between 0 and 12 months. The weight, in Kg, will be measured in a state of fastness ≥ 8h, in participants wearing light clothing without shoes on the same scales calibrated at inclusion and 12 months of follow-up.

    Time frame: 12 months

Secondary outcomes

  1. Weight reduction of at least 5% between 0 and 6 months.

    Weight, in Kg, measured in the same conditon at baseline and 6 months.

    Time frame: 6 months

  2. Weight change between 0 and 6 months

    Weight, in Kg, measured in the same conditon at baseline and 6 months.

    Time frame: 6 months

  3. Weight change between 0 and 12 months

    Weight, in Kg, measured in the same conditon at baseline and 12 months.

    Time frame: 12 months

  4. Waist change between 0 and 6 months

    Waist, in cm, measured midway between the last ribs and the anterior superior iliac crest

    Time frame: 6 months

  5. Waist change between 0 and 12 months

    Waist, in cm, measured midway between the last ribs and the anterior superior iliac crest

    Time frame: 12 months

  6. Triglycerids change between 0 and 12 months

    Plasma fasting levels of triglycerides in g/L

    Time frame: 12 months

  7. HDL cholesterol change between 0 and 12 months

    Plasma fasting levels of HDL cholesterol in g/L

    Time frame: 12 months

  8. LDL cholesterol change between 0 and 12 months

    Plasma fasting levels of LDL cholesterol in g/L

    Time frame: 12 months

  9. non-HDL cholesterol change between 0 and 12 months

    Plasma fasting levels of non-HDL cholesterol in g/L (total cholesterol less HDL-C)

    Time frame: 12 months

  10. Blood glucose change between 0 and 12 months

    Plasma fasting levels of glucose in g/L

    Time frame: 12 months

  11. HbA1c change between 0 and 12 months

    Plasma fasting levels of HbA1c in percentage

    Time frame: 12 months

  12. Systolic blood pressure change between 0 and 12 months

    Systolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer

    Time frame: 12 months

  13. Diastolic blood pressure change between 0 and 12 months

    Diastolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer

    Time frame: 12 months

  14. Triglycerids change between 0 and 6 months

    Plasma fasting levels of triglycerides in g/L

    Time frame: 6 months

  15. HDL cholesterol change between 0 and 6 months

    Plasma fasting levels of HDL cholesterol in g/L

    Time frame: 6 months

  16. LDL cholesterol change between 0 and 6 months

    Plasma fasting levels of LDL cholesterol in g/L

    Time frame: 6 months

  17. non-HDL cholesterol change between 0 and 6 months

    Plasma fasting levels of non-HDL cholesterol in g/L (total cholesterol less HDL-C)

    Time frame: 6 months

  18. Blood glucose change between 0 and 6 months

    Plasma fasting levels of glucose in g/L

    Time frame: 6 months

  19. HbA1c change between 0 and 6 months

    Plasma fasting levels of HbA1c in percentage

    Time frame: 6 months

  20. Systolic blood pressure change between 0 and 6 months

    Systolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer

    Time frame: 6 months

  21. Diastolic blood pressure change between 0 and 6 months

    Diastolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer

    Time frame: 6 months

  22. Change in adherence to the Mediterranean diet : Score PREDIMED

    Change between 0 and 12 months of adherence to mediterranean diet,evaluated by the dietetic score PREDIMED (validated checklist of 14 items). Higher scores indicate greater adherence to the diet assigned

    Time frame: 12 months

  23. Change in adherence to the Mediterranean diet : fruits and vegetables consumption

    Change between 0 and 12 months in terms of perrcentage of consumption of fruits and vegetables on the recommended 400 g/day

    Time frame: 12 months

  24. Change in adherence to the Mediterranean diet : Score PREDIMED

    Change between 0 and 6 months of adherence to mediterranean diet,evaluated by the dietetic score PREDIMED (validated checklist of 14 items). Higher scores indicate greater adherence to the diet assigned

    Time frame: 6 months

  25. Change in adherence to the Mediterranean diet : fruits and vegetables consumption

    Change between 0 and 6 months in terms of percentage of consumption of fruits and vegetables on the recommended 400 g/day

    Time frame: 6 months

  26. Change between 0 and 12 months of Energy intake

    Energy intake, in Kcal/day, evaluated with the validated NAQA questionnaire

    Time frame: 12 months

  27. Change between 0 and 12 months of proteins intake, in g/day, evaluated with the validated NAQA questionnaire

    Time frame: 12 months

  28. Change between 0 and 12 months of sucrose intake in g/day, evaluated with the validated NAQA questionnaire

    Time frame: 12 months

  29. Change between 0 and 12 months of lipids intake in g/day, evaluated with the validated NAQA questionnaire

    Time frame: 12 months

  30. Change between 0 and 12 months of cholesterol intake

    Cholesterol intake, in mg/day, evaluated with the validated NAQA questionnaire

    Time frame: 12 months

  31. Change between 0 and 12 months of calcium intake in mg/day, evaluated with the validated NAQA questionnaire

    Time frame: 12 months

  32. Change between 0 and 12 months of sugary drinks consumption in number of glasses/day

    Time frame: 12 months

  33. Change between 0 and 12 months of alcohol drinks consumption in number of glasses/day

    Time frame: 12 months

  34. Change between 0 and 6 months of sugary drinks consumption in number of glasses/day

    Time frame: 6 months

  35. Change between 0 and 6 months of alcohol drinks consumption in number of glasses/day

    Time frame: 6 months

  36. Change between 0 and 12 months of tobacco consumption in number of cigarettes/day

    Time frame: 12 months

  37. Change between 0 and 6 months of tobacco consumption in number of cigarettes/day

    Time frame: 6 months

  38. Change between 0 and 12 months of Adherence to the WHO recommendations for physical activity, measured in Metabolic Equivalent of Task, MET, evaluated with the GPAQ questionnaire.

    Time frame: 12 months

  39. Change between 0 and 6 months of Adherence to the WHO recommendations for physical activity, measured in Metabolic Equivalent of Task, MET, evaluated with the GPAQ questionnaire.

    Time frame: 6 months

  40. Adherence to OBE-COACH program at 12 months, evaluated by the average percentage of questions (sent by IRIADE) with replies from the subject per week during the previous month.

    Time frame: 12 months

  41. Adherence to OBE-COACH program at 12 months, evaluated by the number of participation in web focus groups over the last 6 months.

    Time frame: 12 months

  42. Adherence to OBE-COACH program at 6 months, evaluated by the average percentage of questions (sent by IRIADE) with replies from the subject per week during the previous month.

    Time frame: 6 months

  43. Adherence to OBE-COACH program at 6 months, evaluated by the number of participation in web focus groups over the last 6 months.

    Time frame: 6 months

  44. Change between 0 and 12 months of Food impulsivity evaluated by the TFEQ21 questionnaire

    Time frame: 12 months

  45. Change between 0 and 6 months of Food impulsivity evaluated by the TFEQ21 questionnaire

    Time frame: 6 months

  46. Evolution between 0 and 12 months of Symptoms of anxiety, measured with the HAD questionnaire (score 0 to 21)

    Time frame: 12 months

08

Study locations

1 site
  • Hôpital La Pitié Salpêtrière
    Paris, 75013, France
09

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jun 2025, 17 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 17 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2025 → Jun 2025 and completion Nov 2026 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2021
First posted
Jun 28, 2021
StartActual
Jan 2, 2024
Primary completionActual
Jun 22, 2025was Nov 2025
CompletionActual
Jun 22, 2025was Nov 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 30, 2026
Primary completion
Nov 15, 2025→Jun 22, 2025 (actual)
Sep 30, 2026
Study completion
Nov 15, 2026→Jun 22, 2025 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Completed
    Primary completion Nov 15, 2025→Jun 22, 2025 (now actual)
    Study completion Nov 15, 2026→Jun 22, 2025 (now actual)
    + 4 other changes: index terms, identifiers, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04941651
Responsible party
Sponsor
First posted
Jun 28, 2021
Start date
Jan 2, 2024
Primary completion
Jun 22, 2025
Completion
Jun 22, 2025
Last update
Sep 30, 2026

Study contacts

Marylou Para, MD, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion